CardioQ-ODM established as a

RNS Number : 4937W

Deltex Medical Group PLC

29 July 2009

 



Deltex Medical Group plc

New studies establish CardioQ-ODM™ as a gold standard

29 July 2009 - Deltex Medical Group plc ('Deltex Medical' or 'Company'), the global leader in oesophageal Doppler monitoring ('ODM'), announces the publication of a new clinical study which establishes its CardioQ-ODM product as the reference technology against which to compare alternative approaches to measuring haemodynamic variables.

The British Journal of Anaesthesia has this month published online a study by doctors from the Medical University of Vienna which investigated the clinical validity during surgery of a new approach to haemodynamic management using Pulse Pressure Waveform Analysis ('PPWA') by comparing results shown using PPWA to results shown using ODM on the same patients undergoing major abdominal surgery. Multiple high quality randomised controlled clinical trials have shown use of ODM to be of significant benefit in patients undergoing major abdominal surgery. For further details see http://bja.oxfordjournals.org/cgi/content/abstract/aep200.

Earlier this year a group of doctors from leading hospitals in France published another study in the British Journal of Anaesthesia comparing data acquired using PPWA to data acquired using ODM both in surgical and intensive care settings where ODM is their standard of care. See http://bja.oxfordjournals.org/cgi/content/short/aep020v1. 

Both studies showed that the PPWA data did not correlate closely enough with the ODM data to allow PPWA to be used as a substitute for ODM.

Andy Hill, Deltex Medical's Chief Executive, commented:

'The high quality evidence base demonstrating the benefits of CardioQ-ODM has led to this major step forward in the technology's status in medical science. To be credible clinically, new devices need to be tested against ODM as it is the only haemodynamic monitoring technology proven to benefit patients during surgery. We expect to see further studies using ODM as the gold standard over the coming months.'

For further information, please contact:-

Deltex Medical Group plc             01243 774 837

Nigel Keen, Chairman                     [e-mail]

Andy Hill, Chief Executive               [e-mail]

Ewan Phillips, Finance Director       [e-mail] 

Nominated Adviser & Broker

Arden Partners plc                       020 7398 1600

Chris Hardie                                   [e-mail]

Matthew Armitt                               [e-mail]

Kreab Gavin Anderson                 020 7554 1400

Deborah Walter                              [e-mail]

Robert Speed                                 [e-mail]

Notes for Editors

Deltex Medical manufactures and markets the CardioQ-ODM™ monitor, which uses disposable ultra-sound probes inserted into the oesophagus to determine the amount of blood being pumped around the body - 'circulating blood volume'. Reduced circulating blood volume is known as hypovolaemia, which leads to insufficient oxygen being delivered to the organs. This causes medical complications including peripheral and major organ failure which can lead to death. Hypovolaemia, which is akin to severe dehydration, affects virtually every patient having surgery because of the combined effects of pre-operative starvation, the impact of the anaesthetic agents and trauma from the surgery itself. Using fluids and drugs, guided by the CardioQ-ODM, to optimise the amount of circulating blood significantly reduces post-operative complications allowing patients to make a faster, more complete recovery and return home earlier.

The CardioQ-ODM incorporates the Company's proprietary software and a small diameter, easy-to-use, minimally invasive, disposable oesophageal probe that is used for transmitting and receiving an ultra-sound signal. By using this technology, the CardioQ-ODM provides clinicians with the ability to haemodynamically optimise critically ill patients and those undergoing routine moderate to major surgery through the controlled administration of fluid and drugs. Haemodynamic optimisation has been scientifically proven to improve the speed and quality of patient recovery and reduce hospital stay.

There are already over 1,500 CardioQ-ODMs currently in use in hospitals worldwide and distribution arrangements are in place in over 30 countries. In addition, there are currently more than 100 clinical publications on the use of the CardioQ-ODM which have repeatedly:-

• Validated the results of the Monitor against known standards for measuring cardiac output, demonstrating that the technology works

• Proved that the CardioQ-ODM works in a wide range of surgical procedures

• Demonstrated that the Company's technology provides significant health and economic benefits by helping to reduce post-operative complications and length of hospital stays by an average of 30 to 40 per cent for a wide range of patients.

The SupraQ™ is an entirely non-invasive device which uses an ultrasound probe held at the base of the patient's neck to track the flow of blood in the aorta; it presents the same data as the CardioQ-ODM in a similar format and is used for taking snapshots or monitoring over short periods.

 

END

 

 

NRARLMTTMMBTBLL